Alzheimer's disease, also known as the "eraser in the mind", is a chronic neurodegenerative disease, one of its main pathological features is the abnormal deposition of β-amyloid (Aβ) in the brain, which forms plaques between neurons, which in turn affects the normal function of nerve cells, and has long lacked effective treatment. Patients and families look forward to a treatment that can truly slow or even reverse the disease progression.
On June 28, the expert team of the Neurology Center of Haici Medical Group successfully implemented targeted drug therapy for patients with Alzheimer's disease, which marked an important step in the treatment of Alzheimer's disease and led the treatment of Alzheimer's disease into a new era of "cause-based treatment".
Ms. Wang, a patient diagnosed with mild Alzheimer's disease and having had memory loss for more than 2 years, came to Haici Medical Group for treatment and was admitted to the fourth ward of the group's neurology center, hoping to retain her memory by receiving standardized anti-Alzheimer's disease systematic treatment.
How to provide patients with better treatment options is an important task for the expert team of the Neurology Center of Haici Medical Group. Miao Dan, director of the neurology center and director of the fourth department, introduced that targeted drug therapy can slow down the progression of Alzheimer's disease by neutralizing and eliminating toxic β-amyloid aggregates found in the brain, has the potential to change the pathology of the disease and alleviate the progression of the disease, and can significantly improve the cognitive function of Alzheimer's disease patients.
According to statistics, there are 38.77 million people aged 60 and above with mild cognitive impairment and about 15.07 million dementia patients, including 13 million patients with mild cognitive impairment of Alzheimer's disease and 9.83 million patients with Alzheimer's disease dementia.
Targeted drug therapy is a humanized immunoglobulin monoclonal antibody against Alzheimer's disease, which can specifically slow the progression of Alzheimer's disease. It is a disease-modifying drug, not a prophylactic drug. China is the third country after the United States and Japan to accelerate its approval for marketing. The current clinical indication is patients with early Alzheimer's disease, mainly including patients with mild Alzheimer's disease or mild cognitive impairment associated with Alzheimer's disease.
Experts remind that early detection, early diagnosis, and early intervention are still very important to delay the development of Alzheimer's disease and improve the recovery. Targeted drug therapy requires rigorous screening and thorough evaluation by a specialist.
The Group's neurology center has rich experience in the diagnosis and treatment of Alzheimer's disease, and the successful use of targeted drug therapy for the first patient in Qingdao has further enhanced the Group's technical level in the field of neurodegenerative disease treatment. The team of the neurology center provides comprehensive protection for the early diagnosis and treatment of Alzheimer's disease patients. Patients who received targeted therapy were rigorously screened to meet the criteria for drug use, and their condition was closely monitored to develop individualized treatment plans for patients. In addition, the department also conducts blood tests for Alzheimer's disease, evaluates the efficacy from the aspect of biomarkers, and further combines drug therapy for dementia rehabilitation.
Department Profile
The Neurology Center of Haici Medical Group is a member of the National Stroke Center Alliance, an advanced stroke center in Shandong Province, and a key discipline in Qingdao. The four departments of the Neurology Center are one of the important departments of the Neurology Center, with 7 physicians (1 chief physician, 2 deputy chief physicians, 3 attending physicians and 1 resident physician), including 1 doctor and 6 masters. The department standardizes the treatment of various cerebrovascular diseases, dementia and cognitive impairment, Parkinson's disease, headache and dizziness, epilepsy, peripheral neuropathy, central nervous system infection and other neurological diseases, and has rich experience in the rescue of difficult and critical diseases of the nervous system.
The department focuses on the standardized treatment of cerebrovascular diseases, with early screening of dementia and cognitive impairment and neurorehabilitation of brain-computer interface as the characteristic direction, routinely carries out electroencephalogram, sleep monitoring, transcranial Doppler (TCD) and other examinations, attaches importance to early rehabilitation of stroke, guides rehabilitation exercises, and minimizes the disability rate of cerebrovascular diseases.
A team of experts
Miao Dan
Chief physician
Director of the Neurology Center of Miaodan Group, Director of the Fourth Department of Neurology, Chief Physician. Graduate. He is also a member of the Rehabilitation Medicine Committee of Shandong Medical Association, the vice chairman of the Physical Medicine and Rehabilitation Professional Committee of Qingdao Medical Association, and the vice chairman of the Rare Disease Branch of Qingdao Medical Association. He was awarded the honorary title of the second outstanding young medical expert of Qingdao. In terms of scientific research, he has participated in 3 national projects and 2 provincial projects as a major project member. He has won 3 second prizes of Provincial Science and Technology Progress Award. He has published 3 SCI papers with the highest impact factor of 5.1.
Specialty: Clinical diagnosis and treatment of dementia and cerebrovascular diseases, rich clinical experience in the diagnosis and treatment of acute and critical cases of the nervous system and incurable diseases, participated in the rescue of acute cerebrovascular diseases, myasthenic crisis gravis, critical Guillain-Barré syndrome, status epilepticus and other neurological critical patients, and participated in the discussion and consultation of large-scale difficult cases for many times.
Consultation time: Thursday morning (specialist clinic, memory clinic)
Wang Qun
Deputy Chief Physician
Deputy Director of the Fourth Department of the Neurology Center of the Group, Deputy Chief Physician, Master of Medicine, graduated from Bethune Medical College of Jilin University, majoring in neurology. At present, he is a member of the Neurology Committee of Shandong Medical Association, a member of Qingdao Anti-Epilepsy Society, a member of the Brain-Heart Therapy Professional Committee of Qingdao Association of Integrative Traditional and Western Medicine, a member of Qingdao Neurology Society, with 2 invention patents, 2 SCI papers, and more than 10 national core journals.
Specialty: Diagnosis and treatment of dizziness, headache, cerebral infarction, cerebral hemorrhage, epilepsy, facial paralysis, insomnia, dementia, multiple sclerosis, Parkinson's disease and other common neurological diseases with integrated traditional Chinese and Western medicine, proficient in the operation and interpretation of video electroencephalogram, especially good at the diagnosis and treatment of neuroimmune system diseases and severe neurological diseases, and also has unique insights into difficult diseases of the nervous system.
Consultation time: Monday morning (neurology clinic, memory clinic)
Fang Chongtao
Deputy Chief Physician
Deputy Chief Physician of the Fourth Department of the Neurology Center of the Group, graduated from Anhui Medical University with a master's degree. Member of the Emergency Medicine Professional Committee of Qingdao Association of Integrative Traditional and Western Medicine. He has published many national papers.
Specialty: Diagnosis and treatment of neurological diseases such as cerebrovascular disease, hypertension, dizziness and headache, insomnia, dementia and cognitive impairment.
Consultation time: Wednesday morning (neurology clinic, memory clinic)